Metrics as of 10/15/2026, 02:18 PM (Berlin time), refresh in progress.
Nuvectis Pharma Stock
Nuvectis Pharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ron Bentsur
- Employees
- 16
- Market cap
- $607 M
- IPO
- 04/02/2022
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various…
Nuvectis Pharma stock: price history
1D
-1.7%
1W
-11.9%
1M
-15.0%
6M
+109.0%
YTD
+146.4%
1Y
+205.4%
2Y
+181.8%
5Y
–
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~96% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Nuvectis Pharma
Analyst assessment of Nuvectis Pharma
PRICE TARGET LOW
US$33.00
CONSENSUS
US$37.33
MEDIAN
US$39.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 24/09/2026
Nuvectis Pharma stock metrics
P/E
-13.74
P/B
46.53
EV/EBITDA
-19.55
RETURN ON EQUITY
-77.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.8%
FLOAT SHARES
21,165,727
AVG. DAILY VOLUME (30D)
196,507
Insider transactions (SEC)
Carson Michael J.
Mosseri Marlio Charles
BENTSUR RON
Hoberman Kenneth
Sanchez Juan
Institutional holders
Comparable stocks
Frequently asked questions about Nuvectis Pharma stock
What does Nuvectis Pharma do?
Nuvectis Pharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ron Bentsur, the company employs around 16 people.
The IPO was on 04/02/2022; the stock trades on NASDAQ under the ticker NVCT.
What do analysts say about Nuvectis Pharma stock?
3 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$37.33, ranging from US$33.00 to US$40.00, with a median of US$39.00.
This is an external assessment, not a statement by Market Jury.
When does Nuvectis Pharma report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 96% stronger than usual.
Does Nuvectis Pharma pay a dividend?
No, Nuvectis Pharma currently does not pay a dividend.
Which stocks are comparable to Nuvectis Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nuvectis Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nuvectis Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.